The Danvers, Mass.-based medical device maker reported fiscal first-quarter sales that missed the mark and lowered its top-line outlook on the rest of the year.
Abiomed posted profits of $88.9 million, or $1.93 per share, on sales of $207.7 million for the three months ended June 3o, for a bottom-line slide of -1.3% on sales growth of 15.4% compared with fiscal Q1 2019. Adjusted to exclude one-time items, earnings per share were $1 even, a penny ahead of the consensus on Wall Street, where analysts were looking for revenues of $211.0 million.
Abiomed said it now expects to report sales of $885 million to $925 million, down from $900 million to $945 million previously.
ABMD shares, which closed down a tick at $278.56 apiece yesterday, were off by -19.3% to $224.75 each today in pre-market trading.